talk with our admissions team to get started.
Contact Us
Pand Health
PROVIDER RESOURCE

Autoimmune Psychosis

Autoimmune psychosis refers to psychotic presentations arising from an underlying antibody-mediated neuroinflammatory process, most commonly anti-NMDA receptor (NMDAR) encephalitis, that can closely mimic and is frequently misdiagnosed as a primary psychiatric disorder such as schizophrenia. The clinical stakes are high because it is treatable with immunotherapy, and delayed treatment worsens outcomes.

Bottom line

Autoimmune psychosis should be actively considered in any new-onset psychosis with atypical features. Roughly 3.5% of first-episode psychosis cases at tertiary centers harbor autoimmune encephalitis, and up to 39% of confirmed cases are initially misdiagnosed as primary psychiatric illness (Fominykh et al., 2025; Ramirez-Bermudez et al., 2025).

The 2020 Pollak et al. international consensus (Lancet Psychiatry) established a possible / probable / definite tiered framework. The single most important action when red flags are present is CSF analysis with paired serum and CSF neuronal antibody testing, not serum alone, because serum-only testing both misses cases and generates false positives.

Distinguishing autoimmune from primary psychosis

The most discriminating clinical features come from a large international multicentre phenotypic analysis comparing NMDAR-antibody encephalitis with primary psychoses, which characterized autoimmune psychosis as a hyperacute, dynamic, stereotyped syndrome, a "delirium praecox," distinct from primary psychosis (Al-Diwani et al., 2026).

FeatureFavors autoimmune psychosisFavors primary psychosis
OnsetUltra-rapid (median 1 day)Gradual (median ~180 days) (Al-Diwani et al., 2026)
Symptom patternPolymorphic, transdiagnostic, sequential (mood → psychotic → disorganized → catatonic within ~2 weeks)Stable within a diagnostic category (Funayama et al., 2022)
Schneiderian first-rank symptomsAbsentPresent (observed only in the schizophrenia group)
HallucinationsVisual and altered perception over-representedAuditory / verbal commenting
Catatonia + deliriumDistinctive combined phenotype (Espinola-Nadurille et al., 2023)Uncommon together
Antipsychotic responseIntolerance or worsening; NMS in 22% of those exposed (Sarkis et al., 2019)Typical response
Seizures, dyskinesias, autonomic instabilityPresentAbsent
Viral prodrome (headache, fever)~70% of anti-NMDAR cases (Gurrera, 2019)Absent
Age / historyOlder; often no prior psychiatric historyYounger; prodrome and psychiatric history common

Red flags that should trigger an extended workup

  • •Disturbance of consciousness or orientation
  • •Catatonia
  • •Speech dysfunction (mutism, verbal reduction)
  • •Focal neurological signs
  • •Seizures or EEG abnormalities
  • •Autonomic dysfunction
  • •Movement disorders / orofacial dyskinesias
  • •Neuroleptic sensitivity

This red-flag set was validated to reduce time-to-diagnosis by 58% in a Charité cohort (Herken & Prüss, 2017; Steiner et al., 2020). An important caveat: in a prospective first-episode psychosis study, 1 of 5 confirmed autoimmune encephalitis cases had no red flags at all, and one had antibodies detectable only in CSF, supporting a low threshold for CSF testing.

Pollak consensus criteria

The framework applies to patients with predominantly psychotic presentations who do not meet full autoimmune encephalitis criteria (Pollak et al., 2020).

Possible

Clinical only

New-onset psychosis plus at least one of: catatonia, dyskinesia or other movement disorder, seizures, neuroleptic malignant syndrome or worsening after antipsychotics, or severe and disproportionate cognitive impairment. This tier gates further investigation.

Probable

Clinical + paraclinical

The above plus at least one of: positive neuronal antibodies (serum or CSF), inflammatory CSF (pleocytosis, elevated IgG index, oligoclonal bands), encephalitic MRI changes, or EEG abnormalities.

Definite

Treatment-confirmed

Probable criteria plus a documented response to an adequate trial of immunotherapy (Luo et al., 2025; Pollak et al., 2020).

Diagnostic workup

1
Antibody testing

Send a first-line panel in both serum and CSF: cell-surface antigens (NMDA-R, CASPR2, LGI1, AMPA-R, GABA-B-R) plus intracellular/onconeural antibodies (Hu, Ri, Yo, CV2/CRMP5, Ma2, amphiphysin, GAD65) and thyroid/ANA. Compartment matters: CSF is more sensitive and specific for anti-NMDAR (serum-only carries a ~14% false-negative rate), whereas serum is more sensitive for LGI1 and CASPR2. Overinterpretation of low-titer serum results (GAD65, VGKC-complex without LGI1/CASPR2) is a leading cause of misdiagnosis.

2
CSF analysis

Cell count, protein, IgG index, and oligoclonal bands. Pleocytosis and oligoclonal bands each carry >96% specificity for an organic rather than primary psychotic etiology. CSF changes appear in ~78% of psychiatric-predominant autoimmune encephalitis, though ~20% can have normal cell counts.

3
EEG

Abnormal in ~61% of cases. The extreme delta brush pattern is specific for anti-NMDAR encephalitis but uncommon.

4
MRI

Abnormal in ~51% overall, but typically unremarkable in anti-NMDAR encephalitis, so a normal MRI does not exclude the diagnosis.

5
Tumor screening

Pelvic imaging for ovarian teratoma, present in up to 58% of young women with anti-NMDAR encephalitis (Dalmau & Graus, 2018).

The complementary neural antibody-based diagnostic algorithm from Budhram et al. underscores that diagnosis should not rely on syndrome-based gating alone, but must integrate best-practice antibody confirmation and exclusion of mimics (Budhram et al., 2024).

Treatment

Immunotherapy is the mainstay, and early treatment is critical. Lack of immunotherapy within 30 days is associated with 2.7-fold increased odds of a poor outcome (Nosadini et al., 2021).

  • First-line

    IV methylprednisolone (corticosteroids), IVIG, and/or plasma exchange, often in combination for severe disease. In a meta-analysis of 1,550 NMDAR encephalitis patients, corticosteroids + IVIG (2.7-fold) and combined first-line regimens were associated with good outcomes.

  • Second-line (no improvement at ~2 weeks)

    Rituximab (preferred; chosen by 80% of experts and associated with 5.9-fold reduced relapse odds) or cyclophosphamide.

  • Third-line / refractory (~10%)

    Bortezomib or tocilizumab; inebilizumab is under investigation in the ExTINGUISH phase 2b trial.

  • Tumor removal

    Resection is essential for recovery when a teratoma is identified.

  • Symptomatic care

    Use antipsychotics cautiously given the high NMS risk. Benzodiazepines (lorazepam) are first-line for catatonia, with ECT reserved for malignant catatonia.

Prognosis

About 80% of anti-NMDAR encephalitis patients achieve substantial recovery at 24 months with treatment and tumor removal, and by one year nearly 60% show no detectable cognitive deficits, a trajectory that differs fundamentally from the stable deficits of schizophrenia (Dalmau & Graus, 2018; Guasp et al., 2022).

Important caveat

Some authorities argue that "autoimmune psychosis" may not be a distinct entity separate from autoimmune encephalitis, and caution that the concept has driven indiscriminate antibody testing in psychiatric populations that neglects pretest probability (Cabrera-Maqueda et al., 2025). The Pollak criteria are expert consensus and have not been prospectively validated in large cohorts. The practical implication is to anchor testing to genuine clinical red flags and always interpret antibody results in the context of CSF findings and phenotype.

References

  1. Abboud, H., Probasco, J. C., Irani, S., et al. (2021). Autoimmune encephalitis: Proposed best practice recommendations for diagnosis and acute management. Journal of Neurology, Neurosurgery, and Psychiatry, 92(7), 757-768.
  2. Al-Diwani, A., Handel, A., Townsend, L., et al. (2019). The psychopathology of NMDAR-antibody encephalitis in adults. The Lancet Psychiatry, 6(3), 235-246.
  3. Al-Diwani, A., Theorell, J., Zghoul, T., et al. (2026). The distinctive psychopathology of NMDAR-antibody encephalitis compared with primary psychoses. The Lancet Psychiatry, 13(1), 47-61.
  4. Binks, S. N. M., Saylor, D., Easton, A., Thakur, K. T., & Irani, S. R. (2026). Encephalitis. Lancet, 407(10542), 1968-1983.
  5. Budhram, A., Irani, S. R., & Flanagan, E. P. (2024). Looking beyond syndrome-based criteria for autoimmune encephalitis. JAMA Neurology, 81(3), 227-228.
  6. Cabrera-Maqueda, J. M., Planagumà, J., Guasp, M., & Dalmau, J. (2025). Autoimmune neuropsychiatric disorders manifesting with psychosis. The Journal of Clinical Investigation, 135(20), e196507.
  7. Dalmau, J., Armangué, T., Planagumà, J., et al. (2019). An update on anti-NMDA receptor encephalitis for neurologists and psychiatrists. The Lancet Neurology, 18(11), 1045-1057.
  8. Dalmau, J., & Graus, F. (2018). Antibody-mediated encephalitis. The New England Journal of Medicine, 378(9), 840-851.
  9. Endres, D., Leypoldt, F., Bechter, K., et al. (2020). Autoimmune encephalitis as a differential diagnosis of schizophreniform psychosis. European Archives of Psychiatry and Clinical Neuroscience, 270(7), 803-818.
  10. Endres, D., Maier, V., Leypoldt, F., et al. (2022). Autoantibody-associated psychiatric syndromes: A systematic literature review resulting in 145 cases. Psychological Medicine, 52(6), 1135-1146.
  11. Espinola-Nadurille, M., Restrepo-Martínez, M., Bayliss, L., et al. (2023). Neuropsychiatric phenotypes of anti-NMDAR encephalitis: A prospective study. Psychological Medicine, 53(9), 4266-4274.
  12. Flanagan, E. P., Geschwind, M. D., Lopez-Chiriboga, A. S., et al. (2023). Autoimmune encephalitis misdiagnosis in adults. JAMA Neurology, 80(1), 30-39.
  13. Fominykh, V., Kovaleva, I., Aksenova, E., et al. (2025). Autoimmune encephalitis in first episode psychosis. Journal of Neuroimmunology, 410, 578815.
  14. Funayama, M., Koreki, A., Takata, T., et al. (2022). Differentiating autoimmune encephalitis from schizophrenia spectrum disorders among patients with first-episode psychosis. Journal of Psychiatric Research, 151, 419-426.
  15. Guasp, M., Rosa-Justicia, M., Muñoz-Lopetegi, A., et al. (2022). Clinical characterisation of patients in the post-acute stage of anti-NMDA receptor encephalitis. The Lancet Neurology, 21(10), 899-910.
  16. Gurrera, R. J. (2019). Frequency and temporal sequence of clinical features in adults with anti-NMDA receptor encephalitis presenting with psychiatric symptoms. Psychological Medicine, 49(16), 2709-2716.
  17. Herken, J., & Prüss, H. (2017). Red flags: Clinical signs for identifying autoimmune encephalitis in psychiatric patients. Frontiers in Psychiatry, 8, 25.
  18. Luo, Y., Sun, H., Fan, J., Zhang, X., & He, Y. (2025). Steroid-responsive autoimmune psychosis with CSF-restricted oligoclonal bands and positive tissue-based assay findings. BMC Psychiatry, 25(1), 691.
  19. Nosadini, M., Eyre, M., Molteni, E., et al. (2021). Use and safety of immunotherapeutic management of NMDA receptor antibody encephalitis. JAMA Neurology, 78(11), 1333-1344.
  20. Pollak, T. A., Lennox, B. R., Müller, S., et al. (2020). Autoimmune psychosis: An international consensus. The Lancet Psychiatry, 7(1), 93-108.
  21. Ramirez-Bermudez, J., Espinola-Nadurille, M., Restrepo-Martinez, M., et al. (2025). Autoimmune psychosis: Psychopathological patterns and outcome after immunotherapy. Schizophrenia Research, 281, 10-19.
  22. Rattay, T. W., Martin, P., Vittore, D., et al. (2021). Cerebrospinal fluid findings in patients with psychotic symptoms. Scientific Reports, 11(1), 7169.
  23. Sarkis, R. A., Coffey, M. J., Cooper, J. J., Hassan, I., & Lennox, B. (2019). Anti-NMDA receptor encephalitis: A review of psychiatric phenotypes and management considerations. The Journal of Neuropsychiatry and Clinical Neurosciences, 31(2), 137-142.
  24. Steiner, J., Prüss, H., Köhler, S., et al. (2020). Autoimmune encephalitis with psychosis: Warning signs, step-by-step diagnostics and treatment. The World Journal of Biological Psychiatry, 21(4), 241-254.
  25. Tanguturi, Y. C., Hanzlik, E., Pagano, L., et al. (2021). Anti-NMDAR encephalitis: Multidisciplinary development of a clinical practice guideline. Hospital Pediatrics, 11(11), 1295-1302.
  26. Venkatesan, A., Michael, B. D., Probasco, J. C., Geocadin, R. G., & Solomon, T. (2019). Acute encephalitis in immunocompetent adults. Lancet, 393(10172), 702-716.
  27. Wong, K. H., Day, G. S., Torner, J. C., et al. (2025). A phase-2b double-blind randomized international prospective trial of inebilizumab in NMDAR encephalitis: The ExTINGUISH trial. Neurology Open Access, 1(2), e000007.

Keep reading

All clinician tools pages →

This page was medically reviewed by Eric Wexler M.D., Ph.D. on August 14, 2026.